Back to Search
Start Over
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials.
- Source :
-
Leukemia [Leukemia] 2007 Sep; Vol. 21 (9), pp. 2020-4. Date of Electronic Publication: 2007 Jul 12. - Publication Year :
- 2007
-
Abstract
- One hundred de novo multiple myeloma patients with t(4;14) treated with double intensive therapy according to IFM99 protocols were retrospectively analyzed. The median overall survival (OS) and event-free survival (EFS) were 41.4 and 21 months, respectively, as compared to 65 and 37 for patients included in the IFM99 trials without t(4;14) (P<10(-7)). We identified a subgroup of patients presenting at diagnosis with both low beta(2)-microglobulin <4 mg/l and high hemoglobin (Hb) >/=10 g/l (46% of the cases) with a median OS of 54.6 months and a median EFS of 26 months, respectively, which benefits from high-dose therapy (HDT); conversely patients with one or both adverse prognostic factor (high beta(2)-microglobulin and/or low Hb) had a poor outcome. The achievement of either complete response or very good partial response after HDT was also a powerful independent prognostic factor for both OS and EFS.
- Subjects :
- Adult
Aged
Chromosomes, Human, Pair 14
Chromosomes, Human, Pair 4
Cytarabine administration & dosage
Dexamethasone administration & dosage
Disease-Free Survival
Female
Follow-Up Studies
Hemoglobins
Humans
Male
Middle Aged
Multiple Myeloma mortality
Multivariate Analysis
Prognosis
Retrospective Studies
Vincristine administration & dosage
beta 2-Microglobulin blood
Antineoplastic Combined Chemotherapy Protocols administration & dosage
Genetic Heterogeneity
Multiple Myeloma drug therapy
Multiple Myeloma genetics
Translocation, Genetic
Subjects
Details
- Language :
- English
- ISSN :
- 0887-6924
- Volume :
- 21
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Leukemia
- Publication Type :
- Academic Journal
- Accession number :
- 17625611
- Full Text :
- https://doi.org/10.1038/sj.leu.2404832